Rituximab as the first-line treatment in newly diagnosed systemic lupus erythematosus

Rituximab as the first-line treatment in newly diagnosed systemic lupus erythematosus

ObjectivesRituximab (RTX) has been commonly used for the treatment of patients with severe or refractory systemic lupus erythematosus (SLE), yet real-world data concerning RTX as the first-line treatment in newly diagnosed moderate-to-severe SLE patients is lacking.MethodsWe conducted a retrospectiv...

Full description

Saved in:
Bibliographic Details
Main Authors: Haiting Wang, Liling Zhao, Shaoying Yang, Huihua Ding, Wanlong Wu, Liqin Yu, Jiajia Jin, Nan Shen, Qiong Fu, Shuang Ye
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Immunology
Subjects:
systemic lupus erythematosus
rituximab
newly diagnosed
disease activity
B cell
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1599473/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1599473/full

Similar Items